Glenmark bucks trend with development of OX40 antagonist for RA, IBD
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has initiated IND-enabling studies of an anti-OX40 monoclonal antibody (GBR 830), potentially a first in class molecule with promise in the area of rheumatoid arthritis and inflammatory bowel disease.